Search

Your search keyword '"Singal, Ashwani"' showing total 1,281 results
Start Over Author "Singal, Ashwani"
1,281 results on '"Singal, Ashwani"'

259. Response to Mancuso et al.

Author

Simonetto, Douglas A., primary, Singal, Ashwani K., additional, Garcia-Tsao, Guadalupe, additional, Caldwell, Stephen H., additional, Ahn, Joseph, additional, and Kamath, Patrick S., additional

Published
2020
Full Text
View/download PDF

271. Pembrolizumab Induced Acute Kidney Injury and Liver Injury in a Patient with Malignant Melanoma.

Author

DeVries, Jonah D., Huber, Mark, Sulaiman, Raed, and Singal, Ashwani K.

Abstract

Immune checkpoint inhibitors (ICIs) have recently gained recognition as valuable treatment options for a variety of cancers. Pembrolizumab is a monoclonal antibody that acts as an inhibitor of programmed cell death receptor-1 (PD1). This helps release host T-cells from regulatory inhibition by tumor neoantigens, therefore mediating antitumor effects. Pembrolizumab has been approved for a variety of cancers including melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and urothelial cell carcinoma. It has also recently gained attention for possible use in hepatocellular carcinoma and triple negative breast cancer. Although efficacious, ICIs manifest a unique set of immune-related adverse effects (irAEs) including acute kidney injury (AKI) and acute liver injury (ALI) of which the mechanism is poorly understood. While these irAEs have been described previously in literature individually, there is a paucity of literature describing their simultaneous occurence. With the growing incorporation of ICIs in oncological regimens, it is important to characterize the presentation of irAEs to facilitate earlier recognition and intervention to avoid further complications. We present a case of a 60-year-old male who presented with concurrent AKI and ALI secondary to pembrolizumab therapy for advanced metastatic melanoma. To the authors’ knowledge, this is the first reported incident in literature of AKI and ALI occurring simultaneously secondary to ICI immunotherapy with pembrolizumab, although each have been reported and characterized individually. [ABSTRACT FROM AUTHOR]

Published
2022

273. Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis

Author

Molnar, Miklos Z., Joglekar, Kiran, Jiang, Yu, Cholankeril, George, Abdul, Mubeen Khan Mohammed, Kedia, Satish, Gonzalez, Humberto C., Ahmed, Aijaz, Singal, Ashwani, Bhamidimarri, Kalyan Ram, Aithal, Guruprasad Padur, Duseja, Ajay, Wong, Vincent Wai-Sun, Gulnare, Agayeva, Puri, Puneet, Nair, Sathees, Eason, James D., and Satapathy, Sanjaya K.

Subjects
surgical procedures, operative, Nonalcoholic steatohepatitis, liver transplantation, graft loss, mortality, renal function, digestive system diseases
Abstract

Background: Nonalcoholic Steatohepatitis(NASH) is one of the top three indications for liver transplantation in western countries. It is unknown whether renal dysfunction at the time of liver transplantation has any effect on post-liver transplantation outcomes in recipients with NASH.Methods: From the United Network for Organ Sharing-Standard Transplant Analysis and Research(UNOS-STAR) dataset, we identified 4,088 NASH recipients who received deceased donor liver transplant. We divided our recipients a priori into three categories: Group I with estimated glomerular filtration rate (eGFR)

Published
2019

277. THU234 - Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease

Author

Younossi, Zobair, Yılmaz, Yusuf, El Kassas, Mohamed, Duseja, Ajay Kumar, Hamid, Saeed Sadiq, Esmat, Gamal, Méndez-Sánchez, Nahum, Chan, Wah-Kheong, Singal, Ashwani, Ong, Janus, Lam, Brian, Felix, Sean, Younossi, Elena, Verma, Manisha, Price, Jillian, Nader, Fatema, Younossi, Issah, Racila, Andrei, and Stepanova, Maria

Published
2022
Full Text
View/download PDF

278. THU069 - Lean non-alcoholic fatty liver disease patients from the global NASH registry

Author

Younossi, Zobair, Yılmaz, Yusuf, Yu, Ming-Lung, Wong, Vincent Wai-Sun, Castellanos-Fernandez, Marlen, Isakov, Vasily, Duseja, Ajay Kumar, Méndez-Sánchez, Nahum, Eguchi, Yuichiro, Bugianesi, Elisabetta, Burra, Patrizia, George, Jacob, Fan, Jian-Gao, Papatheodoridis, George, Chan, Wah-Kheong, Alswat, Khalid, Hamid, Saeed Sadiq, Singal, Ashwani, Gomez, Manuel Romero, Gordon, Stuart C, Roberts, Stuart, El Kassas, Mohamed, Kugelmas, Marcelo, Ong, Janus, Alqahtani, Saleh, Ziayee, Mariam, Lam, Brian, Younossi, Issah, Racila, Andrei, Henry, Linda, and Stepanova, Maria

Published
2022
Full Text
View/download PDF

279. THU034 - Alcohol associated hepatitis in Latin America: results from the AH-LATIN study

Author

Arnold, Jorge, Diaz, Luis Antonio, Idalsoaga, Francisco, Ayares, Gustavo, Fuentes, Eduardo, Ramirez, Carolina, Medel, María Paz, Ferreccio, Catterina, Lazo, Mariana, Roblero, Juan Pablo, Brahmania, Mayur, Carbonetti, Rodolfo, Marciano, Sebastián, Mendizabal, Manuel, Bessone, Fernando, Romero, Gustavo, Palazzo, Ana, Manero, Estela Florencia, Dirchwolf, Melisa, Piombino, Diego, Valverde, María Ayala, Cairo, Fernando, Gracia Villamil, Maria Alejandra, Rodriguez Gazari, Maria Mercedes, Gallardo, Patricia, Ramos, Geraldine, Guerra, Patricia, Silveira, Fabio, Chaves, Roberta, Silva, Giovanni, Lobato, Cirley, Lemos, Jozelda, Alves, Rogério, Pereira, Gustavo, de Cássia Martins Alves da Silva, Rita, Costa Mendes, Liliana Sampaio, Couto, Cláudia Alves, Rocha, Cristina Melo, Lazarte, Raul, Yaquich, Pamela, Norero, Blanca, Jure, Camila, Dominguez, Alejandra, Vicar, Marta Mac, Rivas, Violeta, Arancibia, Juan Pablo, Sierralta, Armando, Valera, Jose, Diaz, Sebastian, Sanchez, Carlos, Toro, Luis, Varon, Adrian, Correa, Elizabeth, Restrepo, Juan Carlos, Tapias, Monica, Rosales, Ricardo Aguilera, Infante, Mirtha, Pazmiño, Galo, Armijos, Xiimena, Carrera, Enrique, Ligoria, Regina, Avila, Gerson, Sanchez, Abel, Sánchez, Marco, Mejia, Scherezada, Cordova, Jacqueline, De Fatima Higuera de La Tijera, Maria, Contreras, Raul, Solis, Francisco, Varela, Jesus, Jacobo, Janett, Velarde-Ruiz Velasco, Jose Antonio, Quezada, Julissa Lombardo, Veramendi, Esther, Vela, Victor, Pamo, Claudia, Puma, Donny, Marcelo, Julio, Tenorio, Laura, Cabrera, Maria, Rivera, Jose, Montes, Pedro, Bataller, Ramon, Louvet, Alexandre, Shah, Vijay, Kamath, Patrick S., Singal, Ashwani, Arrese, Marco, and Arab, Juan Pablo

Published
2022
Full Text
View/download PDF

280. OS110 - The number of public health policies reduces the burden and mortality of alcohol-associated liver disease worldwide: a call for action

Author

Diaz, Luis Antonio, Fuentes, Eduardo, Idalsoaga, Francisco, Arnold, Jorge, Ayares, Gustavo, Cannistra, Macarena, Vio, Danae, Márquez, Andrea, Corsi, Oscar, Villalón, Alejandro, Ramirez, Carolina, Medel, María Paz, Ferreccio, Catterina, Lazo, Mariana, Roblero, Juan Pablo, Kulkarni, Anand, Kim, Won, Brahmania, Mayur, Louvet, Alexandre, Tapper, Elliot, Dunn, Winston, Simonetto, Douglas, Shah, Vijay, Kamath, Patrick S., Singal, Ashwani, Bataller, Ramon, Arrese, Marco, and Arab, Juan Pablo

Published
2022
Full Text
View/download PDF

287. Impact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among US Veterans With Steatotic Liver Disease.

Author

Wong, Robert J., Yang, Zeyuan, Cheung, Ramsey, Singal, Ashwani K., Do, Albert, Ahmed, Aijaz, and Yeoh, Aaron

Abstract

Conflicting data exist on the impact of alcohol use on risk of liver disease progression in patients with steatotic liver disease. We aimed to evaluate the effect of longitudinal alcohol use on risk of cirrhosis among veterans with steatotic liver disease. US veterans with steatotic liver disease were identified from January 2010 through December 2022. Alcohol use was assessed using documented Alcohol Use Disorders Identification Test-Concise (AUDIT-C) scores and categorized as no alcohol (AUDIT-C = 0), low-risk alcohol use (AUDIT-C 1–2 for women and 1–3 for men), and high-risk alcohol (AUDIT-C ≥ 3 for women and ≥ 4 for men). Incidence of cirrhosis was evaluated with competing risks Nelson-Aalen methods. Adjusted multivariable regression models evaluated risks of cirrhosis associated with baseline alcohol use and changes in alcohol use during follow-up. There were 1,156,189 veterans with steatotic liver disease identified (54.2% no alcohol, 34.6% low-risk alcohol, and 11.2% high-risk alcohol). Veterans with steatotic liver disease and high-risk alcohol have a 43% higher incidence of cirrhosis compared with patients reporting no alcohol use. Compared with patients with baseline high-risk alcohol who reported no change in alcohol use, those who decreased their alcohol use during follow-up experienced a 39% reduction in long-term risk of cirrhosis (hazard ratio, 0.61; 95% CI, 0.45–0.83; P <.01). One in 9 veterans with steatotic liver disease report concurrent high-risk alcohol use, which is associated with 43% greater risk of cirrhosis compared with no alcohol use. However, reducing alcohol use lowers risk of cirrhosis, emphasizing the importance of timely alcohol use assessment and early interventions to address high-risk alcohol use in steatotic liver disease. [Display omitted] High-risk alcohol use in adults with steatotic liver disease increases the risk of liver disease progression. Timely alcohol use assessment and early interventions to address high-risk alcohol use are critical, particularly in patients with steatotic liver disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

295. Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria

Author

Phillips, John, primary, Farrell, Collin, additional, Wang, Yongming, additional, Singal, Ashwani K., additional, Anderson, Karl, additional, Balwani, Manisha, additional, Bissell, Montgomery, additional, Bonkovsky, Herbert, additional, Seay, Toni, additional, Paw, Barry, additional, Desnick, Robert, additional, and Bloomer, Joseph, additional

Published
2019
Full Text
View/download PDF

299. Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria

Author

Naik, Hetanshi, primary, Overbey, Jessica R., additional, Desnick, Robert J., additional, Anderson, Karl E., additional, Bissell, D. Montgomery, additional, Bloomer, Joseph, additional, Bonkovsky, Herbert L., additional, Phillips, John D., additional, Wang, Bruce, additional, Singal, Ashwani, additional, and Balwani, Manisha, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results